RSV vaccine approved for use in at-risk over-50s The new TGA approval allows access to the Arexvy vaccine for at-risk adults aged 50–59, expanding the previous indication.
Longer pollen season bringing more risk for asthma patients Research shows the hay fever season is growing longer, and one expert says GPs are at the forefront of helping patients reduce complications.
Study examines whether RSV vaccine lasts ‘at least three winters’ The results of a randomised controlled trial indicate an RSV vaccine could offer protection against the virus over three seasons in over 60s.
General practice pilot to ease ‘significant impacts’ of hay fever To boost low adherence to treatments, a new trial aims to support GPs through a tailored education toolkit used alongside daily nasal spray.
Queensland makes pharmacy prescribing permanent The RACGP has called out the decision to make the pilot programs a permanent fixture, raising concerns about patient safety and the precedent it sets.
GPs emphasise the power of social prescribing The college has called for more investment into non-medical activities to boost wellbeing, particularly in more remote areas of Australia.
‘Get up to speed’: GPs admit climate change knowledge gaps A survey found 80% of GPs are concerned about its health impacts, but say their practice is not doing enough to address the issue.
Opioid agonist treatment prevents hundreds of suicides: Study Australian research predicts the treatment has prevented around 300 suicide deaths among NSW patients with opioid use disorder.
First Arexvy safety data released The Australian-first safety data found 63% of recipients experienced no side effects in the first three days after vaccination.
Medical Council backs Rural Generalist recognition Rural generalism is on the verge of being recognised as its own specialty, with an application to be submitted to the Council of Health Ministers for approval.